CNS Pharmaceuticals, Inc.
Cash Flow History
| Period | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| Mar 2019 | $-82.7K | $-82.7K | $0 | $44.0K |
| Jun 2019 | $-616.9K | $-625.3K | $8.4K | $69.8K |
| Sep 2019 | $-378.3K | $-378.3K | $0 | $172.9K |
| Dec 2019 | $-2.5M | $-2.5M | $11.7K | $190.3K |
| Mar 2020 | $-1.9M | $-1.9M | $6.4K | $242.2K |
| Jun 2020 | $-2.7M | $-2.8M | $11.5K | $323.2K |
| Sep 2020 | $-1.3M | $-1.3M | $0 | $365.0K |
| Dec 2020 | $-1.4M | $-1.4M | $0 | $362.9K |
| Mar 2021 | $-3.3M | $-3.3M | $3.7K | $430.7K |
| Jun 2021 | $-5.0M | $-5.0M | $0 | $469.6K |
| Sep 2021 | $-2.0M | $-2.0M | $0 | $506.6K |
| Dec 2021 | $-3.2M | $-3.2M | $2.1K | $316.9K |
| Mar 2022 | $-3.1M | $-3.1M | $0 | $336.7K |
| Jun 2022 | $-3.4M | $-3.4M | $2.9K | $286.8K |
| Sep 2022 | $-1.8M | $-1.8M | $1.5K | $289.7K |
| Dec 2022 | $-2.3M | $-2.3M | $-1 | $289.7K |
| Mar 2023 | $-4.8M | $-4.8M | — | $290.3K |
| Jun 2023 | $-3.4M | $-3.4M | — | $289.7K |
| Sep 2023 | $-3.4M | $-3.4M | — | $194.8K |
| Dec 2023 | $-2.5M | $-2.5M | — | $232.7K |
| Mar 2024 | $-3.2M | $-3.2M | — | $202.9K |
| Jun 2024 | $-1.7M | $-1.7M | — | $234.3K |
| Sep 2024 | $-6.8M | $-6.8M | — | $271.8K |
| Dec 2024 | $-5.5M | $-5.5M | — | $129.9K |
| Mar 2025 | $-3.2M | $-3.2M | $0 | $62.4K |
| Jun 2025 | $-5.3M | $-5.3M | $0 | $22.0K |
| Sep 2025 | $-2.2M | $-2.2M | — | $18.3K |
| Dec 2025 | $-3.1M | $-3.1M | — | $85.1K |
| Mar 2026 | $-4.6M | $-4.7M | $6.2K | $2.6K |
| Jun 2026 | $-3.5M | $-3.5M | $3.8K | $2.0K |